Literature DB >> 32535501

The transitional phase of multiple sclerosis: Characterization and conceptual framework.

Ingo Kleiter1, Ilya Ayzenberg2, Joachim Havla3, Carsten Lukas4, Iris-Katharina Penner5, Christine Stadelmann6, Ralf A Linker7.   

Abstract

The conversion of relapsing-remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS) cannot be defined by a sharp threshold determined by event-based measures, but rather represents a gradual process. In consequence, there may exist a transitional phase between RRMS and clearly established SPMS. So far, transitional MS has been poorly characterized in terms of patient properties, course of disease and therapeutic interventions that may delay conversion to SPMS. Furthermore, the pathogenesis of transitional MS is incompletely understood, and no definitive imaging or laboratory test informs when exactly a patient has entered the transitional MS phase. Here we review the current knowledge and evidence characterizing the transitional phase of MS and propose potential designs and criteria for a prospective clinical study in patients with transitional MS.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker; Disease course; Disease modifying therapy; Progressive multiple sclerosis; Trial design

Mesh:

Year:  2020        PMID: 32535501     DOI: 10.1016/j.msard.2020.102242

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  2 in total

Review 1.  Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics.

Authors:  Emily Kamma; Wendy Lasisi; Cole Libner; Huah Shin Ng; Jason R Plemel
Journal:  J Neuroinflammation       Date:  2022-02-10       Impact factor: 8.322

Review 2.  Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective.

Authors:  Giacomo Lus; Marco André Bassano; Vincenzo Brescia Morra; Simona Bonavita; Antonio Gallo; Davide Maimone; Laura Malerba; Giorgia Teresa Maniscalco; Francesco Saccà; Giuseppe Salemi; Renato Turrini; Salvatore Cottone; Edoardo Sessa; Maria Buccafusca; Luigi Maria Edoardo Grimaldi
Journal:  Neurol Sci       Date:  2022-09-17       Impact factor: 3.830

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.